jrnl590

Publication Venue For

  • State of the Art: the Not-So-Great Wall of America.  21. 2019
  • Epicardial Adipose Tissue and Cardiovascular Disease.  21. 2019
  • Unanswered Questions Regarding Blood Pressure Management for HF Prevention.  21. 2019
  • Obesity and Pulmonary Hypertension.  20. 2018
  • Out of Office Blood Pressure Measurement in Pregnancy and the Postpartum Period.  20. 2018
  • Novel Medical Treatments for Hypertension and Related Comorbidities.  20. 2018
  • Visceral Adipose Tissue Accumulation and Residual Cardiovascular Risk.  20. 2018
  • A Systematic Review of Sleep, Hypertension, and Cardiovascular Risk in Children and Adolescents.  20. 2018
  • Masked Hypertension.  19. 2017
  • Regression of Left Ventricular Mass After Bariatric Surgery.  19. 2017
  • Sex-Specific Contributions of Endothelin to Hypertension.  20. 2017
  • Obesity-Associated Hypertension: the Upcoming Phenotype in African-American Women.  19. 2017
  • Pathophysiology and Potential Non-Pharmacologic Treatments of Obesity or Kidney Disease Associated Refractory Hypertension.  19. 2017
  • Sleep Disordered Breathing: Hypertension and Cardiac Structure and Function.  17. 2015
  • Mechanisms Influencing Circadian Blood Pressure Patterns Among Individuals with HIV.  17. 2015
  • Coronary Heart Disease Risk Factors and Outcomes in the Twenty-First Century: Findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.  17. 2015
  • Inflammation and Hypertension: New Understandings and Potential Therapeutic Targets.  17. 2014
  • Alterations in cardiac structure and function in hypertension.  16. 2014
  • Therapy of acute hypertension in hospitalized children and adolescents.  16. 2014
  • Vitamin D deficiency in the pathogenesis of hypertension: Still an unsettled question.  16. 2014
  • Mechanisms of lipotoxicity in the cardiovascular system.  14:517-531. 2012
  • Epidemiology of obesity, the metabolic syndrome, and chronic kidney disease.  14:152-159. 2012
  • Vitamin D therapy and cardiovascular health.  13:187-191. 2011
  • A stitch saves time and lowers blood pressure.  12:146-148. 2010
  • Heme oxygenase and renal disease.  11:56-62. 2009
  • Beyond brachial pressure effect..  10:213-215. 2008
  • Neurohormonal regulation of the sympathetic nervous system: New insights into central mechanisms of action.  10:233-240. 2008
  • Leptin and mechanisms of endothelial dysfunction and cardiovascular disease..  10:434-439. 2008
  • Antihypertensive effects of drospirenone and 17beta-estradiol in hypertensive postmenopausal women..  9:209-210. 2007
  • Are current guidelines optimal for treatment of blood pressure in patients with coronary artery disease?.  9:211-213. 2007
  • Uric acid and hypertension.  8:111-115. 2006
  • Adding low-dose spironolactone to multidrug regimens for resistant hypertension..  6:211-212. 2004
  • The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack (ALLHAT) Trial: focus on the diabetic patient..  6:212-214. 2004
  • Effects of hormone replacement therapy on the sympathetic nervous system and blood pressure..  5:241-246. 2003
  • Do angiotensin receptor antagonists have benefits beyond blood pressure lowering?.  4:219-220. 2002
  • Effects of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs.  3:227-228. 2001
  • Health outcomes associated with calcium antagonists.  3:228-229. 2001
  • The role of the nervous system in hypertension.  3:255-262. 2001
  • Aldosterone-related genetic effects in hypertension.  2:295-301. 2000
  • Angiotensin converting enzyme inhibitors: Are they preferred first-line therapy?.  2:392-397. 2000
  • Antihypertensive drug therapy in the third millennium: Are there benefits beyond blood pressure?.  2:291-294. 2000
  • Recent outcome trials of newer antihypertensives.  1:238-240. 1999
  • The epithelial sodium channel in hypertension.  1:158-163. 1999
  • The role of the central nervous system in hypertension.  1:246-253. 1999